Sorry! We are editing this page
Subscribe to our Newsletter and we will notify you when it’s available.
Subscribe now […]
Two case histories. Model projects which changed the way insurance documents and medicine information were designed.
With the support of our Donors, Members, and Volunteers from around the world, we are developing new international guidelines and model templates for consumer medicine information and labelling. Join us.
Consumer Medicine Information (CMI) in Australia is designed to provide accurate, up-to-date information to consumers about prescription medicines and pharmacy-only medicines. Individual CMI leaflets (CMIs) should provide all the information users might need about a specific medicine product. CMI is provided in the wider context of health information as a communication and counselling link between healthcare providers and medicine consumers. That, at least, is what should happen…
Consumer Medicine Information (CMI) in Australia has been ready for a makeover since the 1990s, even before we published the first edition of Writing About Medicines for People in 1994.
Just before you get excited: there is no such thing as best practice in CID. ‘Best practice’ implies that only one kind of acceptable practice exists. But this is […]
This Model CRI Project was undertaken to demonstrate how the application of information design methods could lead to better medicine label usability. Along with a later projects, it was instrumental in bringing about a change in the regulations for Over The Counter (OTC) Medicines.
If the draft labelling regulations proposed by TGA are implemented without major change, medicine labelling will become unusable at an acceptable level by at least 50% of literate consumers..
In Australia, where responsibility for government regulation of medicine information is in the hands of the Therapeautic Goods Administration (TGA) we are about to see bad design required by regulation.
Suddenly, the Therapeutic Goods Administration (TGA) is an expert in typography and information design. The TGA has proposed a new set of guidelines for medicine labelling, to replace the evidence-based approach in TGO69A and the ASMI Code of Practice. If implemented, the new guidelines will result in more medication errors and a gradual deterioration of medicine labelling usability in Australia.